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3-Aminobenzamide and/or 06-benzylguanine evaluated as an adjuvant to
temozolomide or BCNU treatment in cell lines of variable mismatch repair
status and 06-alkylguanine-DNA alkyltransferase activity
SR Wedge, JK Porteous and ES Newlands
Department ofMedical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Summary 06-benzylguanine (06-BG) and 3-aminobenzamide (3-AB) inhibit the DNA repair proteins o6_
alkylguanine-DNA alkyltransferase (AGT) and poly(ADP-ribose) polymerase (PARP) respectively. The effect
of 06-BG and/or 3-AB on temozolomide and 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) cytotoxicity, was
assessed in seven human tumour cell lines: six with an AGT activity of >80 fmol mg-' protein (Mer+) and
one with an AGT activity of <3 fmol mg protein (Mer-). Three ofthe Mer+ cell lines (LS174T, DLD1 and
HCT116) were considered to exhibit resistance to methylation by a mismatch repair deficiency (MMR-), each
being known to exhibit microsatellite instability, and DLD1 and HCT116 having well-characterised defects in
DNA mismatch binding. Potentiation was defined as the ratio between an IC50 achieved without and with a
particular inhibitor treatment. Temozolomide or BCNU cytotoxicity was not potentiated by either inhibitor in
the Mer- cell line. Preincubation with 06-BG (100 /M for 1 h) was found to potentiate the cytotoxicity of
temozolomide by 1.35- to 1.57-fold in Mer+/MMR+ cells, but had no significant effect in Mer+/MMR- cells.
In comparison, 06-BG pretreatment enhanced BCNU cytotoxicity by 1.94- to 2.57-fold in all Mer+ cell lines.
Post-incubation with 3-AB (2 mm, 48 h) potentiated temozolomide by 1.35- to 1.59-fold in Mer+/MMR+ cells,
and when combined with 06-BG pretreatment produced an effect which was at least additive, enhancing
cytotoxicity by 1.97- to 2.16-fold. 3-AB treatment also produced marked potentiation (2.20- to 3.12-fold) of
temozolomide cytotoxicity in Mer+/MMR- cells. In contrast, 3-AB produced marginal potentiation of BCNU
cytotoxicity in only three cell lines (1.19- to 1.35-fold), and did not enhance the cytotoxicity of BCNU with o6_
BG treatment in any cell line. These data suggest that the combination of an AGT and PARP inhibitor may
have a therapeutic role in potentiating temozolomide activity, but that the inhibition ofpoly(ADP-ribosyl)ation
has little effect on the cytotoxicity of BCNU.
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Temozolomide, a monofunctional methylating imidazotetra-
zinone, and BCNU, a bifunctional chloroethylnitrosourea,
represent two different classes of chemotherapeutic alkylating
agent. The anti-tumour activity of both compounds is
dependent upon formation of a reactive alkyldiazonium ion
(Weinkam and Lin, 1979; Denny et al., 1994) and subsequent
alkylation of the accessible nucleophilic atoms of DNA,
predominantly N7-guanine, followed by N3-adenine and o6-
guanine (Roberts, 1978). Temozolomide cytotoxicity can
largely be accredited to methylation of 06-guanine (Domor-
adzki et al., 1984; Margison and O'Connor, 1990) and N3-
adenine (Karran et al., 1982); the cytotoxicity/mutagenicity of
06-methylguanine being attributed to the induction of futile
cycling in the long patch mismatch repair pathway, which
results in prolonged DNA strand interruptions and the
inhibition of subsequent replication (Ceccotti et al., 1993;
Karran et al., 1993). In contrast, the cytotoxicity of BCNU
correlates with formation of a l-[N3-deoxycytidyl]-2-[N1-
deoxyguanosinyl]-ethane DNA interstrand cross-link (Bodell
et al., 1985; Jiang et al., 1989), which is produced by
intramolecular rearrangement of an 06-chloroethylguanine
adduct (Tong et al., 1982a).
Temozolomide has recently demonstrated promising
clinical activity in the treatment of glioblastoma and
melanoma (Newlands et al., 1992; O'Reilly et al., 1993),
while BCNU is an established agent for the treatment of
many malignancies, including glioma and lymphoma (Young
et al., 1971; Edwards et al., 1980). Nevertheless, the activity
of DNA-alkylating chemotherapy is frequently compromised
by the development of resistance; a phenomenon often
related to the DNA repair capacity of the tumour cell
(Harris et al., 1983; Ludlum, 1990). It is therefore possible
that the inhibition of one or more DNA-repair processes, by
appropriate pharmacological intervention, may circumvent
such resistance. This approach has been most widely
examined with inhibitors of AGT, a DNA-repair protein
responsible for the stoichiometric removal of adducts
produced at the 06-position of guanine (Pegg, 1983; Tano
et al., 1990). O6-guanine adduct removal irreversibly
inactivates AGT, requiring de novo synthesis of the protein
to restore activity (Pegg, 1990). AGT depletion with the
substrate analogue 06-BG has been found to increase the
cytotoxicity of both temozolomide and BCNU in vitro
(Dolan et al., 1991; Zeller and Magull-Seltenreich, 1995;
Wedge et al., 1996a), and their anti-tumour activity in
xenograft experiments (Dolan et al., 1993; Felker et al., 1993;
Friedman et al., 1995; Wedge et al., 1996b). More
importantly, the administration of 06-BG has been shown
to increase the therapeutic index of BCNU in vivo (Mitchell
et al., 1992; Gerson et al., 1993). However, there may be a
need to identify additional DNA-repair mechanisms which
can be inhibited to further potentiate DNA-alkylating
therapies. This may be particularly relevant to temozolo-
mide, since a methylation-tolerant phenotype can develop
from a deficiency in the methyl-directed mismatch repair
pathway (Branch et al., 1993; Kat et al., 1993; Karran et al.,
1994), which fails to recognise 06-methylguanine and produce
DNA strand breakage. Thus, increasing the retention of o6_
methylguanine by treatment with 06-BG would not be
expected to potentiate temozolomide cytotoxicity in a
mismatch repair-deficient cell line.
An additional target for manipulation may be PARP, an
abundant chromatin-bound enzyme, which has been impli-
cated as having a regulatory role in many cellular processes,
including DNA repair (Satoh et al., 1993). Unmodified
PARP binds tightly to DNA strand breaks, but is released
following auto-poly(ADP-ribosyl)ation (Satoh and Lindahl,
1992). It is suggested that this mechanism may function to
prevent spurious transcription or recombination during
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normal DNA metabolism, or may impede DNA synthesis to
prevent replication on a damaged template (Satoh and
Lindahl, 1992; Chatterjee and Berger, 1994). PARP may
also have a role in nucleosomal unfolding, since it can ADP
ribosylate and electrostatically displace histones (Althaus et
al., 1994; Buki et al., 1995), which would relieve chromatin
condensation and facilitate the accessibility of the strand
interruption to DNA repair enzymes. Activation of PARP in
vitro has been demonstrated following treatment with a
number of methylating agents, including dimethyl sulphate
(Durkacz et al., 1980), N-methyl-N'-nitro-N-nitrosoguanidine
(Juarez-Salinas et al., 1979), methyl methanesulphonate
(Satoh et al., 1993), streptozotocin (Whish et al., 1975) and
temozolomide (Tisdale, 1985), while PARP inhibition with 3-
AB has been found to enhance methylating cytotoxicity
(Durkacz et al., 1980; Biirkle et al., 1987). PARP activation
has also been implicated in response to treatment with a
variety of DNA cross-linking agents, which include BCNU
(Malapetsa et al., 1995).
The effects of combining an AGT and PARP inhibitor, or
inhibiting PARP in a mismatch repair-deficient cell line, have
not been examined in relation to methylating agent
cytotoxicity. In addition, relatively few studies have examined
chloroethylnitrosourea cytotoxicity and PARP inhibition. The
main aim ofthis study, therefore, was to determine the relative
enhancement of temozolomide or BCNU cytotoxicity by
treatment with 06-BG and/or 3-AB in cell lines ofvaried AGT
activity and mismatch repair status.
Materials and methods
Chemicals and drugs
Temozolomide was kindly supplied by Dr J Catino, Schering-
Plough Research Institute, Kenilworth, NJ, USA, and BCNU
was purchased from Bristol Myers Pharmaceuticals, Houn-
slow, Middlesex, UK. 06-BG and the [3H]methyl-labelled
DNA substrate for the assay of AGT were generous gifts
from Dr RC Moschel (NCI-Frederick Cancer Research and
Development Center, Frederick, MD, USA) and Dr GP
Margison (Paterson Institute for Cancer Research, Christie
Hospital NHS Trust, Manchester, UK) respectively. All other
chemicals were purchased from Sigma, Poole, UK.
Cell culture
Seven human cell lines were examined: four colorectal
adenocarcinomas (Mawi, LS174T, HCT116 and DLD1), a
breast adenocarcinoma (MCF-7), a malignant melanoma
(StML-1 la) and a glioblastoma astrocytoma (U87MG).
Mawi was established at Charing Cross Hospital (Baer et
al., 1993), HCT116 and DLD1 obtained from Dr P Karran
(Imperial Cancer Research Fund, Clare Hall Laboratories,
South Mimms, Hertfordshire, UK), StML-Ila from Dr C
Zouboulis (Department of Dermatology, The Free University
of Berlin, Germany), and all other cell lines from the
European Tissue Culture Collection, Porton Down, UK.
Cell lines were grown as monolayers in Dulbecco's modified
Eagle medium (DMEM) or Roswell Park Memorial Institute
1640 tissue culture medium (RPMI-1640) (ICN Biomedicals,
High Wycombe, UK), supplemented with 10% heat-
inactivated fetal calf serum (FCS; Gibco, Paisley, UK), L-
glutamine (2 mM), penicillin (100 U ml-') and streptomycin
(100 Mg ml-'). Cultures were maintained in exponential
growth at 37°C in a humidified 5% carbon dioxide incubator.
Assay ofAGT activity
AGT activity was measured as removal of o6_
[3H]methylguanine from a 3H-methylated DNA substrate, as
previously described (Lee et al., 1991; Wedge et al., 1996a).
The AGT activity of an extract was expressed as fmol of
[3H]CH3 transferred from the DNA substrate per mg of
protein, using the assay of Bradford et al. (1976).
Cytotoxicity assay
Cytotoxicity was evaluated in 96-well plates as previously
described (Wedge et al., 1996a), using the sulphorhodamine-B
(SRB) assay for protein (Skehan et al., 1990). Conditions for
06-BG incubation were chosen from AGT depletion data. 3-
AB incubation conditions were selected from experiments in
which 3-AB had been shown to inhibit DNA strand break
rejoining and enchance methylating agent cytotoxicity
(Durkacz et al., 1980; Burkle et al., 1987). Both inhibitor
treatments (alone and in combination) were determined to be
non-growth inhibitory in each cell line. Briefly, cells were
plated 24 h before a 1 h preincubation with 0.5% ethanol in
DMEM or RPMI-1640, with/without 06-BG (100 /iM).
Medium was then removed from all plates and replaced
with that containing either temozolomide (3 h) or BCNU
(1 h). Following drug incubation, medium was replenished
with 0.2% dimethyl sulphoxide (DMSO) in DMEM or
RPMI-1640 with/without 3-AB (2 mM). The medium of all
plates was replaced with drug-free medium 48 h later, and
plates reincubated for a further 5 days before SRB assay. IC50
values were interpolated by cubic spline regression. Potentia-
tion of temozolomide or BCNU cytotoxicity by 06-BG and/
or 3-AB was taken to be the ratio between the ICso achieved
without inhibitor treatment divided by the IC50 achieved with
inhibitor treatment.
Statistical analysis and evaluation of combination responses
The significance of a reduction in IC50, obtained by pre- or
post-incubation with a DNA repair inhibitor, was analysed
using a one-tailed unpaired Student's t-test. The combined
effect of 06-BG and 3-AB on temozolomide cytotoxicity was
evaluated using the multiple drug effect analysis of Chou
and Talalay (1984), by treating 'temozolomide+O6-BG' and
'temozolomide+3-AB' as two separate 'drugs'. Dose-effect
curves were constructed following each individual experi-
ment for each 'drug' and for the combination in a fixed
ratio (1: 1) multiple dilution series, using the median effect
equation (Chou, 1991). Computer software (Chou and
Chou, 1987) was used to calculate a combination index
(CI), with CI values of less than 1 being indicative of
synergy, values of greater than 1 antagonism, and values
equal to 1 additivity.
Results
AGT activity
The AGT activities of HCT-116 and DLD-1 were determined
to be 87+4.7 and 442+ 17 fmol mg-' protein respectively
(mean+s.e. from three independent samples). These activities
were less than 10% of the control value (i.e. to 5.0+0.7 and
9.9+ 1.4 fmol mg-' protein, respectively), 24 h after incuba-
tion with 06-BG (100 /uM, 1 h). Basal AGT activities of
U87MG, StML-Ila, LS174T, Mawi, and MCF-7 were
previously determined to be 2.5, 113, 197, 535 and
721 fmol mg-' protein respectively (Wedge et al., 1996a).
Depletion of AGT activity in these cell lines (by 100 4uM o6_
BG for 1 h) was similar to that observed in DLD-1 and
HCT-116.
Potentiation of cytotoxicity by 06-BG and/or 3-AB
No significant enhancement of temozolomide or BCNU
cytotoxicity was observed in U87MG, following either
pretreatment with 06-BG or post-treatment with 3-AB
(P>0.1, Tables I and II). The low AGT activity of this
cell line combined with an inherent sensitivity to temozolo-
mide alone, would correlate with a Mer-/MMR+ pheno-
type. The six remaining cell lines with intermediate/high
AGT activities (Mer+) were classified according to whether
they were mismatch repair competent (MMR+) or deficient
(MMR-). Those cell lines considered mismatch repairPotentiation of temozolomide by 06-BG and 3-AB
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Table I Cytotoxicity of temozolomide with or without 06-BG and/or 3-AB
Temozolomide IC50 (#mM)
Without With 06-BG
Phenotype Cell line 06-BG or 3-AB With 06-BG With 3-AB and 3-AB
Mer-MMR+ U87MG 11+2.0 9.8+0.9 11+2.6 10+1.6
Mer+MMR+ StML-lla 376+40 238± 12 279+24 181±5.9
Mawi 719+40 515+50 462+42 335+8.5
MCF-7 801 +27 599+36 583 ±43 403±41
Mer+MMR- HCT116 502+ 31 489±46 225+ 25 187+27
LS174T 1132+15 1068+29 531 +7.5 508+22
DLDI 1015+87 881 +89 338+38 295+32
IC5, values were determined 7days after a 3h incubation with temozolomide, with/without 06-BGpretreatment (100gM, 1 h) and/or 3-AB post-
treatment (2mM, 48h). Values represent the mean+s.e. calculated from three separate experiments.
Table H Cytotoxicity of BCNU with or without 06-BG and/or 3-AB
BCNUIC50 (#mM)
Without With 06-BG
Phenotype Cell line 06-BG or 3-AB With 06-BG With 3-AB and 3-AB
Mer-MMR+ U87MG 53+4.3 47+±2.9 57+1.3 59+2.7
Mer+MMR+ StML-lla 119+12 46+1.8 103+14 51+4.6
Mawi 203+3.7 105+1.6 170+4.8 109+4.3
MCF-7 192+15 92+5.1 157+6.2 79+6.7
Mer+MMR- HCT116 65+1.2 28+3.9 46+2.3 23+ 1.7
LS174T 159+4.5 65+5.4 143+ 11 69+7.9
DLDI 141+10 62+0.6 132+6.6 59+1.6
IC50 values were determined 7days after a 1 h incubation with BCNU, with/without 06-BG pretreatment (100,M, 1 h) and/or 3-AB post
treatment (2nm, 48h). Values represent the mean+s.e. calculated from three separate experiments.
deficient were DLD-1 (indistinguishable from HCT15) and
HCT-116, which have mutations in the mismatch repair
genes GTBP/pl60 and hMLHI respectively (Branch et al.,
1995; Drummond et al., 1995), and LS174T, in which AGT
depletion does not potentiate temozolomide cytotoxicity
(Wedge et al., 1996a), and which demonstrates microsatel-
lite instability characteristic of a mismatch repair deficiency
(Shibata et al., 1994).
Temozolomide Pretreatment with 06-BG significantly re-
duced the ICs0 of temozolomide in Mer+/MMR+ cell lines
(P<0.015, Table I), and when 3-AB post-treatment was
combined with 06-BG pretreatment and temozolomide, it
significantly increased the cytotoxicity of the 06-BG and
temozolomide combination (P<0.01). Temozolomide cyto-
toxicity was enhanced to a similar extent by either 06-BG
pretreatment (1.35- to 1.57-fold) or 3-AB post-treatment
(1.35- to 1.59-fold), and a combination of 06-BG and 3-AB
treatment enhanced temozolomide cytotoxicity by 1.97- to
2.16-fold (Figure la). CI values (mean+s.d.) determined at
the IC50 were 0.68+0.10 and 0.79+0.14 for mutually
exclusive and non-exclusive combinations respectively,
suggesting that the effect of combining an AGT and PARP
inhibitor produces an approximately additive (if not slightly
synergistic) enhancement of temozolomide cytotoxicity in
Mer+/MMR+ cell lines.
In contrast, the IC50 of temozolomide in Mer+/MMR-
cell lines was not reduced significantly by 06-BG (P>0.05),
but very significantly reduced by 3-AB (Table I, P,<0.0002):
treatment with 3-AB potentiating temozolomide cytotoxicity
by 2.20-3.12-fold (Figure lb).
BCNU 06-BG pretreatment significantly reduced the IC50 of
BCNU in both Mer+/MMR+ (P<0.003) and Mer+/MMR-
(P<0.001) cell lines (Table II), thereby potentiating the
cytotoxicity of BCNU by 1.94- to 2.57-fold (Figure 2). Post-
treatment with 3-AB produced marginal potentiation (1.19-
to 1.35-fold) of BCNU cytotoxicity in Mawi, MCF-7 and
HCT116 (Figure 2). However, the addition of 3-AB to a
combination of 06-BG and BCNU did not significantly
reduce the IC50 value obtained in any cell line (P>0.05, Table
II).
Discussion
While AGT depletion has been widely shown to potentiate
the cytotoxicity of both methylating and bifunctional
chloroethylating agents, studies investigating PARP inhibi-
tion and cytotoxicity have predominantly focused upon
methylating agents such as dimethyl sulphate (Durkacz et
al., 1980), N-methyl-N'-nitro-N-nitrosoguanidine (Nduka et
al., 1980) and temozolomide (Boulton et al., 1995). Although
it has been suggested that the enhancement of BCNU
cytotoxicity by the nucleoside analogue tiazofurin is related
to the inhibition of PARP activity (Berger et al., 1985), an
additional study has indicated that the cytotoxicity of the
bifunctional nitrosoureas is unaffected by PARP inhibition
(Sebolt-Leopold and Scavone, 1992).
A wealth of experimental evidence suggests that there is
some association between PARP activity and DNA strand
breakage (Berger et al., 1979; Durkacz et al., 1980; Shall,
1984; Satoh and Lindahl, 1992). The mechanism by which 3-
AB potentiates cytotoxicity could therefore be related to the
alkylation of N7-guanine and N3-adenine by temozolomide
(Bull, 1988) and BCNU (Tong et al., 1982b), which can lead
to DNA strand breakage following either enzymatic (Dianov
and Lindahl, 1994) or spontaneous (Bailly and Verly, 1988)
depurination. These strand breaks are likely to be bound by
PARP (Satoh and Lindahl, 1992). The inhibition of PARP
auto(ADP-ribosyl)ation would therefore impede the release
of PARP from DNA (and/or nucleosomal unfolding),
thereby preventing gap closure and potentiating the
cytotoxicity of DNA-alkylating compounds.
A relationship between PARP and DNA strand breakage
would support the findings of this study as follows:
(1) Temozolomide cytotoxicity in Mer+/MMR+ cells is
dependent upon both the processing of 06-methylgua-
nine by a functional mismatch repair pathway and DNA
strand breakage following depurination of 3-methylade-
nine and 7-methylguanine. These separate cytotoxic
events can be independently enhanced by treatment
with 06-BG and 3-AB respectively, and an approxi-
mately additive response is obtained when the inhibitors
are combined (Figure la).
(2) In Mer+/MMR- cells temozolomide cytotoxicity isPotentiation of temozolomide by 06-BG and 3-AB
SR Wedge et al !
1033
a
T T
T
StML11a Mawi MCF-7
Mer+/MMR+ Cell lines
3.5
StML11a Mawi MCF-7
Mer+/MMR+ Cell lines
mT
3.0
0
0
(a
a)
0o
HCT116 LS174T DLD1
Mer+/MMR Cell lines
Figure 1 Potentiation of temozolomide cytotoxicity by 06-BG
pretreatment (=I ), 3-AB post-treatment ( ), or a combination
of 06-BG and 3-AB treatments (_), in (a) Mer+/MMR+ and
(b) Mer+/MMR- cell lines. Cell lines within each group are
arranged in order of increasing AGT activity. 'Potentiation' was
defined as the ratio between an IC50 achieved without and with a
particular inhibitor treatment. Each bar represents the mean
potentiation+s.e. from three independent experiments.
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Figure 2 Potentiation of BCNU cytotoxicity by 06-BG (L ), 3-
AB (M), or a combination of 06-BG and 3-AB (_). Symbols
are as for Figure 1.
entirely dependent upon lesions resulting in strand
breakage, and so only treatment with 3-AB can
potentiate cell killing (Figure lb).
(3) Any potentiation of BCNU cytotoxicity is independent
of methyl-directed mismatch correction. The significant
enhancement of BCNU cytotoxicity in Mer+ cell lines
following treatment with 06-BG (Figure 2) is a
consequence of increasing the number of highly toxic
DNA interstrand cross-links (Lown et al., 1978).
Although PARP is known to bind to BCNU-damaged
DNA (Malapetsa et al., 1995), 3-AB produced little
enhancement of BCNU cytotoxicity suggesting that
DNA strand breakages arising from N7-guanine and
N'-adenine adducts constitute only a minor effect
towards BCNU cytotoxicity. This result supports the
findings of Sebolt-Leopold and Scavone (1992).
(4) The lack of potentiation of either temozolomide or
BCNU cytotoxicity by 3-AB in the U87MG Mer-/
MMR+ cell line (Tables I and II) may suggest that
DNA strand breakage also contributes little towards cell
death in cells which are inherently very sensitive to DNA
adducts produced at 06-guanine.
These interpretations are complicated by a number of
factors, not least that concentrations of 3-AB exceeding 1 mM
can also inhibit mono(ADP-ribosyl) transferases (Rankin et
al., 1989), while even greater concentrations can induce
perturbations in DNA precursor metabolism (Milam et al.,
1986). However, that treatment with 3-AB for 48 h did not
inhibit the growth of any cell line (data not shown), and that
the enhancement of temozolomide and BCNU cytotoxicity by
3-AB was profoundly different in the same cell line (e.g.
DLDI, Figure 1 and 2), would suggest that the potentiation
observed is unlikely to be related to an effect of 3-AB on DNA
synthesis. An effect on ADP(ribose) metabolism is most
probable, given that 3-AB (1 mM) can completely inhibit a
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50% reduction in cellular NAD produced by treatment with
2 mM temozolomide (Boulton et al., 1995). The association
between DNA strand breakage and the inhibition of PARP
with 3-AB, however, remains controversial (Boulton et al.,
1995), and it is possible that the enhancement of temozolo-
mide cytotoxicity by 3-AB could be related to the inhibition of
acceptor protein ADP-(ribosyl)ation, particularly if such
proteins regulate cell cycle progression or apoptosis in
response to DNA damage (Kastan et al., 1991; Nosseri et
al., 1994; Malcomson et al., 1995).
The magnitude by which methylation and chloroethylation
cytotoxicity was enhanced by 06-BG did not clearly correlate
with AGT activity, although resistance to both agents can be
multifactorial and dependent on factors other than at the
level of DNA repair. These may include drug-detoxification
mechanisms, involving glutathione-S-transferase (Smith et al.,
1989; Waxman, 1990) or metallothionine (Kelley et al., 1988).
In addition, the p53 injury-response pathway, which induces
G, arrest and/or apoptosis in response to DNA damage
(Kastan et al., 1991; Malcomson et al., 1995), may also
contribute to drug resistance following mutational events or
overexpression of bcl-2 (Miyashita and Reed, 1992; Fairburn
et al., 1994).
One concern with the use of DNA repair inhibitors is the
increase in normal tissue toxicity from DNA-alkylating
chemotherapy (Fairburn et al., 1995), particularly the
exacerbation of myelosuppression which is dose limiting for
both BCNU and temozolomide. However, this may be
clinically managed by appropriate bone marrow and
haematopoietic support. The possible enhancement of
mutagenesis by AGT depletion, particularly with a methylat-
ing agent (Yang et al., 1994), should be treated with greater
trepidation, although the potential short-term therapeutic
gain may well outweigh this risk in patients with an otherwise
dismal prognosis.
In conclusion, these data indicate that the inhibition of
poly(ADP-ribosyl)ation has little effect on the cytotoxicity of
BCNU, but that a combination of AGT and PARP inhibitor
may have a useful therapuetic role in potentiating
temozolomide activity. This study also emphasises that the
use of a PARP inhibitor to enhance methylating agent
activity will be unaffected by mismatch repair status. Further
investigation of the concentration and schedule dependency
of 3-AB as a potentiator of temozolomide cytotoxicity may
therefore be warranted, although the clinical potential of
PARP inhibition will only be realised if more potent and
soluble inhibitors become available.
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Temozolomide, 8-carbamoyl-3-methylimidazo[5,1-da-1,2,3,5-tetra-
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06-benzylguanine; 3-AB, 3-aminobenzamide.
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